Vnitr Lek 2010, 56(7):736-738

Diabetic osteopathy: previously disputed but most likely important ailment

Š. Svačina
III. interní klinika 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA

Diabetic osteopathy is usually not mentioned in the list of diabetic complications. This osteopathy is very important in clinical medicine. In the pathogenesis many factors are involved - bone formation, hyperglycaemia, glycosuria, glycation of collagene etc. Clinically important is the high risk of fractures present in diabetic patients. This risk can be positively and negatively modified by antidiabetic drugs. It is important to find some markers for fracture risk in diabetes. Nowadays only bone densitometry can be used with some limitations to quantify this risk.

Keywords: diabetic osteopathy; bone fracture; antidiabetic drugs; risk markers

Received: May 26, 2010; Published: July 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Svačina Š. Diabetic osteopathy: previously disputed but most likely important ailment. Vnitr Lek. 2010;56(7):736-738.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Vencovský J. Muskuloskeletální projevy u diabetes mellitus. In: Svačina Š et al (eds). Poruchy metabolismu a výživy. Praha: Galén 2010.
    2. Sobotka L. Sarkopenie seniorů. In: Svačina Š et al (ed). Poruchy metabolismu a výživy. Praha: Galén 2010.
    3. Isidro ML, Ruano B. Bone disease in diabetes. Curr Diabetes Rev 2010; 6: 144-155. Go to original source... Go to PubMed...
    4. Schwartz AV. Diabetes Mellitus: Does it Affect Bone? Calcif Tissue Int 2003; 73: 515-519. Go to original source... Go to PubMed...
    5. Leidig-Bruckner G, Ziegler R. Diabetes mellitus a risk for osteoporosis? Exp Clin Endocrinol Diabetes 2001; 109 (Suppl 2): S493-S514. Go to original source... Go to PubMed...
    6. Raska I Jr, Broulík P. The impact of diabetes mellitus on skeletal health: an established phenomenon with in established causes? Prague Med Rep 2005; 106: 137-148. Go to PubMed...
    7. Amano A, Kawai S. Diabetes and oral osteoporosis. Clin Calcium 2007; 17: 186-191. Go to PubMed...
    8. Lalla E, Lamster IB, Feit M et al. Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice. J Clin Invest 2000; 105: 1117-1124. Go to original source... Go to PubMed...
    9. Won HY, Park JB, Park EY et al. Effect of hyperglycemia on apoptosis of notochordal cells and intervertebral disc degeneration in diabetic rats. J Neurosurg Spine 2009; 11: 741-748. Go to original source... Go to PubMed...
    10. Li H, Jiang LS, Dai LY. High glucose potentiates collagen synthesis and bone morphogenetic protein-2-induced early osteoblast gene expression in rat spinal ligament cells. Endocrinology 2010; 151: 63-74. Go to original source... Go to PubMed...
    11. Fantuzzi G, Mazzone TH. Adipose tissue in health and disease. Totowa: Humana Press 2007. Go to original source...
    12. Haluzík M, Svačina Š. Metabolické jaderní receptory PPAR. Praha: Grada Publishing 2004.
    13. Shockley KR, Lazarenko OP, Czernik PJ et al. PPARg2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells. J Cell Biochem 2009; 106: 232-246. Go to original source... Go to PubMed...
    14. Botushanov NP, Orbetzova MM. Bone mineral density and fracture risk in patients with type 1 and type 2 diabetes mellitus. Folia Med (Plovdiv) 2009; 51: 12-17.
    15. Adami S. Bone health in diabetes: considerations for clinical management. Curr Med Res Opin 2009; 25: 1057-1072. Go to original source... Go to PubMed...
    16. Strotmeyer ES, Cauley JA, Schwartz AV et al. Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med 2005; 165: 1612-1617. Go to original source... Go to PubMed...
    17. Kahn SE, Zinman B, Lachin JM et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008; 31: 845-851. Go to original source... Go to PubMed...
    18. Palička V. Léky ovlivňující kostní metabolismus u diabetiků. Vnitř Lék 2009; 55: 368-370. Go to PubMed...
    19. Svačina Š. Diabetes, antidiabetika a kost. Čas Lék čes 2010; 149: 282-284.
    20. Gao Y, Li Y, Xue J et al. Effect of the anti-diabetic drug metformin on bone mass in ovariectomized rats. Eur J Pharmacol 2010; 635: 231-236. Go to original source... Go to PubMed...
    21. Yamada C, Yamada Y, Tsukiyama K et al. The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology 2008; 149: 574-579. Go to original source... Go to PubMed...
    22. Kimura T, Kuwata T, Ashimine S et al. Targeting of bone-derived insulin-like growth factor-II by a human neutralizing antibody suppresses the growth of prostate cancer cells in a human bone environment. Clin Cancer Res 2010; 16: 121-129. Go to original source... Go to PubMed...
    23. Matsumura M, Monden T, Nakatani Y et al. Effect of raloxifene on serum lipids for type 2 diabetic menopausal women with or without statin treatment. Med Princ Pract 2010; 19: 68-72. Go to original source... Go to PubMed...
    24. Schulz TJ, Tseng YH. Emerging role of bone morphogenetic proteins in adipogenesis and energy metabolism. Cytokine Growth Factor Rev 2009; 20: 523-531. Go to original source... Go to PubMed...
    25. Hruska KA, Mathew S, Saab G. Bone morphogenetic proteins in vascular calcification. Circ Res 2005; 97: 105-114. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.